Clinical significance of HGF and NMP22 of voided urine tests for post-operative bladder cancer
-
摘要: 目的：探讨膀胱尿路上皮癌术后检测尿肝细胞生长因子（HGF）和核基质蛋白22（NMP22）表达水平在肿瘤复发监测中的临床价值。方法：2005年1月~2009年6月收治膀胱尿路上皮癌患者92例（接受TURBT或膀胱部分切除术者），术后2周开始规律性膀胱灌注化疗药物吡柔比星（THP）。采用酶联免疫吸附法（ELISA）分别检测灌注前、灌注6周、6个月和12个月时尿中HGF和NMP22的含量；对照组为31例健康人。结果：92例膀胱癌患者术后12个月有11例复发，复发率12%。未复发者尿HGF和NMP22含量随膀胱灌注时间的延长呈下降趋势，肿瘤复发时却明显升高，与对照组比较，差异有统计学意义（P<0.05）；尿HGF、NMP22含量和尿脱落细胞学检查（VUC）对膀胱尿路上皮癌术后复发诊断的敏感性分别为91%、73%和45%，特异性分别为58%、48%和98%，阳性预测值分别为100%、80%和71.4%，阴性预测值分别为57%、48%和93%。结论：检测尿HGF和NMP22含量可以作为膀胱尿路上皮癌术后肿瘤复发监测及早期诊断的有效指标，二者结合具有较高的敏感性和预测性。Abstract: Objective: To evaluate clinical significance of Hepatocyte Growth Factor(HGF) and Nuclear Matrix Protein 22(NMP22) of voided urine tests in detecting the relapse of post-operative bladder cancer. Method: A total of 92 patients (males 79, females 13) with bladder cancer and 31 healthy volunteers enrolled in this study were classified into two groups:post-operative patients with bladder cancer were used pirarubicin(THP); 31 heathly volunteers.The voided urine of all the patients in before, 6weeks, 6 months, 12 months post perfusion were recovered selectively. HGF and NMP22 kits were used to detect bladder cancer. Voided urine cytology(VUC) was used to compare the sensitivity and specificity of the screening test.Result: There were 11 cases who relapsed in 92 patients with perfusion in 12 months.The level of HGF and NMP22 decreased with the prolong of perfusing time.There were mostly increased in the relapse of bladder cancer. The sensitivity and specificity of HGF, NMP22 and VUC were 91%, 73%, 45% and 58%, 48%, 98% respectively. The VUC has the lowest sensitivity among the screening tests. The HGF and NMP22 with the sensitivity can be an adjunct to cytology for evaluating relapse of bladder cancer.Conclusion: The HGF and NMP22 test has a better correlation with the relapse of the bladder cancer. They might be promising tools for screening and early diagnosing bladder cancer.
-
Key words:
- bladder cancer /
- HGF /
- NMP22 /
- diagnosis
-
-
[1] KAUFMAN D S, SHIPLEY W U, FELDMAN A S. Bladder cancer[J]. Lancet, 2009, 374(9685):239-249.
[2] 杨为民,卢童. 常用激光技术治疗表浅性膀胱肿瘤的现况[J]. 临床泌尿外科杂志,2008,23(7):485-488.
[3] 扑永锋,刘鹏,扑春南. NMP22在膀胱癌诊断中的研究进展[J]. 肿瘤学杂志,2008,14(2):154.
[4] ABEL P D. Prognostic indices in transitional cell carcinoma of the bladder[J]. Brit J Urol, 1998,62:103.
[5] 高建国,田涛,宋亚林等. 围手术期大剂量吡柔比星膀胱灌注预防膀胱癌复发的临床观察[J].中华外科杂志,2010,48(21):1650-1652.
[6] 罗金荣. 膀胱内灌注吡柔比星防治膀胱癌切除术后复发48例疗效分析[J]. 中国临床研究,2011,20(7):593-594.
[7] HADDAD R, LIPSON K, WEBB C P. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors[J]. Anticancer reseach, 2001, 21:4243-4252.
[8] ROSEN E M, JOSEPH A, JIN L, et al. Regulation of scatter factor production via a soluble inducing factor[J]. J Cell Biol, 1994, 127(1):225-259.
[9] JOSEPH A, WEISS G H, JIN L, et al. Expression of scatter factor in human bladder carcinoma[J]. J. Natl. Cancer Inst, 1995, 87(5):372-379.
[10] LI B, KANAMARU H, NORIKI S, et al. Differential expression of hapatocyte growth factor in papillary and nodular tumors of the bladder[J]. Int J Urol, 1998, 5(5):436-476.
[11] GHOUSSOUB R A, DILKON D A, AQUILA T, et al. Expression of c-met is a strong independent prognostic factor in breast carcinoma[J]. Cancer, 1998, 82:1513-1520.
[12] BEREZNEY R, COFFEY D S. Identification of a unclear protein matrix[J]. Biochem Biophys Res Commun, 1974, 60:1410-1417.
[13] KEESEE S K, BRIGGMAN J V, THILL C, et al. Utilization of unclear matrix protein for cancer diagnosis[J]. Crit Rev Eukaryot gene Ext, 1996, 6(2):189-214.
[14] GROSSMAN H B, SOLOWAY M, MESSING E, et al. Surveillance for recurrent bladder cancer using a point of care protenmic assay[J]. JAMA, 2006, 295:299-305.
[15] 苏大军,宋力. 尿核基质蛋白22在膀胱移行细胞癌诊断和术后复发监测中的应用[J]. 第四军医大学学报,2007,28(8):706-708.
[16] 马利民,张跃平,张芹等. 尿核基质蛋白检测在膀胱癌诊断中的应用价值评定[J]. 临床泌尿外科杂志,2005,20(3):175-177.
-
计量
- 文章访问数: 174
- PDF下载数: 129
- 施引文献: 0
下载: